research use only
Cat.No.S7029
| Related Targets | HDAC ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase eIF |
|---|---|
| Other PARP Inhibitors | XAV-939 AZD5305 (Saruparib) Veliparib (ABT-888) PJ34 HCl AG-14361 Iniparib (BSI-201) Pamiparib G007-LK UPF 1069 A-966492 |
|
In vitro |
DMSO
: 79 mg/mL
(199.78 mM)
Ethanol : 31 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 395.43 | Formula | C22H22FN3O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1174043-16-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | COC1CCN(CC1)C(=O)C2=C(C=CC(=C2)CC3=NNC(=O)C4=CC=CC=C43)F | ||
| Targets/IC50/Ki |
PARP
|
|---|---|
| In vitro |
AZD2461 has lower affinity for Pgp. |
| In vivo |
AZD2461 has an 80-fold increased Mdr1b expression on -resistant KB1P tumor T6-28, without inhibition of Pgp. This compound induces loss of 53BP1 expression in mice with KB1P tumors with short-term treatment. Long-term treatment with this chemical is well tolerated and doubled the median relapse-free survival. |
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01247168 | Completed | Refractory Solid Tumors|Cancer Tumor |
AstraZeneca |
November 2010 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
I need to formulate it for in vivo use. How to dissolve this compound for injections?
Answer:
The IP formula of this compound is 3% DMSO+40% PEG+2% Tween-80+H2O, the concentration of which can be up to 5 mg/ml. And you must add solvents to it in order and individually.